Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
This trial aim to explore whether short-course tislelizumab (3 cycles of 200 mg q3w in the induction phase and 3 cycles of 400 mg q6w in the consolidation phase) yields non-inferior event-free survival compared to long-course tislelizumab (3 cycles of 200 mg q3w in the induction phase and 5 cycles of 400 mg q6w in the consolidation phase) in patients with locoregionally advanced nasopharyngeal carcinoma.
Epistemonikos ID: e7a72ef17ec009221f57fb6a96bec9fe135ddec4
First added on: Jan 29, 2026